← Back to Search

Blood Thinner for Radial Artery Occlusion (CAPITAL-RAPTOR Trial)

Phase 3
Recruiting
Research Sponsored by Ottawa Heart Institute Research Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age ≥ 18 years
Diagnostic coronary angiography or percutaneous coronary intervention via the transradial approach
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days
Awards & highlights

CAPITAL-RAPTOR Trial Summary

This trial will test whether a blood thinner can reduce the risk of a common complication from a heart procedure.

Who is the study for?
This trial is for adults who've had a coronary angiography or heart intervention via the wrist artery and can consent to participate. It's not for those with upcoming surgeries, certain heart issues, pregnancy without birth control, bleeding risks, severe liver or kidney disease, recent strokes, allergies to rivaroxaban, or on specific drugs.Check my eligibility
What is being tested?
The study tests if taking Rivaroxaban (a blood thinner) orally once daily for a week after wrist artery access can prevent the artery from closing up. This complication happens in about 5% of cases and prevents future use of this artery.See study design
What are the potential side effects?
Rivaroxaban may cause bleeding problems including serious internal bleeds. Other possible side effects include allergic reactions and liver enzyme changes which could indicate liver damage.

CAPITAL-RAPTOR Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I have had a heart vessel examination or treatment through my wrist.

CAPITAL-RAPTOR Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Primary efficacy outcome - rate of radial artery occlusion
Primary safety outcome - International Society on Thrombosis and Haemostasis definition of major bleeding
Secondary outcome measures
All cause mortality
BARC bleeding criteria
Bleeding requiring medical attention
+8 more

CAPITAL-RAPTOR Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: RivaroxabanExperimental Treatment1 Intervention
Participants will receive rivaroxaban 15mg tablet to be taken orally once daily for 7 days. Follow up will be within 30 days where participants will undergo a Doppler ultrasound to assess for radial artery patency/occlusion.
Group II: Standard of CareActive Control1 Intervention
Participants will not receive any anticoagulation. Follow up will be within 30 days where participants will undergo a Doppler ultrasound to assess for radial artery patency/occlusion.

Find a Location

Who is running the clinical trial?

Ottawa Heart Institute Research CorporationLead Sponsor
188 Previous Clinical Trials
90,774 Total Patients Enrolled
1 Trials studying Radial Artery Occlusion
700 Patients Enrolled for Radial Artery Occlusion

Media Library

Rivaroxaban 15 MG Oral Tablet [Xarelto] Clinical Trial Eligibility Overview. Trial Name: NCT03630055 — Phase 3
Radial Artery Occlusion Research Study Groups: Rivaroxaban, Standard of Care
Radial Artery Occlusion Clinical Trial 2023: Rivaroxaban 15 MG Oral Tablet [Xarelto] Highlights & Side Effects. Trial Name: NCT03630055 — Phase 3
Rivaroxaban 15 MG Oral Tablet [Xarelto] 2023 Treatment Timeline for Medical Study. Trial Name: NCT03630055 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the FDA cleared Rivaroxaban 15 MG Oral Tablet [Xarelto] for public use?

"Rivaroxaban 15 MG Oral Tablet [Xarelto] is a Phase 3 trial drug, meaning that there is both evidence of its efficacy and multiple rounds of data indicating its safety. Our team rates it as a 3 on our safety scale."

Answered by AI

Are patients currently being accepted into this trial?

"That is accurate. The 1800 patients that this study needs are currently being recruited from 2 clinical sites. Information about the trial was first posted on October 3rd, 2018 and the most recent update occurred on February 8th, 2022."

Answered by AI

Does this research mark a new development in medical science?

"Rivaroxaban 15 MG Oral Tablet [Xarelto] has been under clinical study since 2015. The first trial was sponsored by Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma and had 2180 participants. After the initial Phase 3 approval in 2015, there are currently 62 active trials involving Rivaroxaban 15 MG Oral Tablet [Xarelto] being conducted across 45 nations and 403 cities."

Answered by AI

What are the standard effects of Rivaroxaban 15 MG Oral Tablet [Xarelto]?

"Rivaroxaban 15 MG Oral Tablet [Xarelto] is an effective medication for the treatment of venous thromboembolism, chronic coronary artery disease, and deep vein thrombosis."

Answered by AI

How many people are allowed to take part in this research project at any one time?

"That is correct, the online information hosted on clinicaltrials.gov affirms that this study is still recruiting patients. The details of the posting state that it was put up on October 3rd, 2018 and last updated February 8th, 2022. Currently, the plan is to have 1800 people take part in the trial at 2 locations."

Answered by AI
Recent research and studies
~440 spots leftby Dec 2025